Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States. Gomez GB, Nelson CB, Rizzo C, Shepard DS, et al. J Infect Dis 2022;226.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gomez GB, Nelson CB, Rizzo C, Shepard DS, et al. Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States. J Infect Dis 2022;226.
PMID: 35968865